ABMI... Anyone else out there have this stock? LET'S TALK Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ABMI... Anyone else out there have this stock? LET'S TALK

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John William Bowman who wrote (22)	12/18/1996 1:20:00 AM
From: John William Bowman	of 37

I just got this off the wires, ABMI unchanged today 1 5/16 THE WOODLANDS, Texas--(BUSINESS WIRE)--Dec. 17, 1996--American BioMed Inc. (NASDAQ OTC BB:ABMI), Tuesday announced that the company in collaboration with Dr. Samuel S. Ahn plans to launch an innovative product line of flexible silicone balloon infusion catheters for thrombectomy and thrombolysis in the second quarter of 1997, which will expand the company's existing product line. Prototypes are currently being tested at UCLA and 510(K) submission to the FDA is expected to be completed in February 1997. Dr. Samuel S. Ahn, American BioMed's principal clinical investigator, said: "I design new products based on my own experience in the operating room and what I perceive as more efficient and beneficial to the patient as well as the surgeon that will perform the surgical procedure. I believe these products will provide surgeons with increased effectiveness, safety and user-friendliness and represent an improvement over existing products now on the market." Company President and CEO, Steven B. Rash, stated: "We continue to be encouraged that surgeons and other professionals in the medical community are choosing our all silicone balloon catheters over the alternative latex products. We expect this trend to continue given the inherent life threatening problems that latex allergy poses in operating rooms today. We are being aggressive with our commercialization efforts and we anticipate further improvement in market share for our products. These latest products are an excellent example of our strategic plan to utilize our existing technologies and bring quality products to market in order to enhance our top-line growth through stronger revenue streams." American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. I will write when I get more info John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next